Is BELLUS HEALTH INCORPORATED (BLUSF) a Buy? The Stock Is in Investors Sights

May 19, 2017 - By Louis Casey

Is BELLUS HEALTH INCORPORATED (BLUSF) a Buy? The Stock Is in Investors Sights

Interested investors have been looking for information on shares of BELLUS HEALTH INCORPORATED (OTCMKTS:BLUSF) after the stock moved $0.008, hitting the $0.204 price point in a recent trade.

It’s the latest price, but let’s analyze how the stock has been doing recently. In the past year, BELLUS HEALTH INCORPORATED’s stock was big mover. According to the short interest report published recently, (BLUSF) had 1,400 shorted shares for 0.1 days to cover. The prior short interest was 2,300 for a $-39.13 change. The 52-Week High and Low are noted here. -90.93 % (High), 20.00 %, (Low). The stock had 14,900 average volume.

Enroll for Our Newsletter Today and know if shares price of BELLUS HEALTH INCORPORATED (OTCMKTS:BLUSF) is Ready to Breakout!

Penny stocks are often stated as risky investments that hardly pay off. Admittedly, there is fact to this, but with the right knowledge and tactics, it is possible to earn a significant amount of gain in penny stocks. Simply said, a penny stock is an equity that trades at a low price.

Irrespective of the name, penny stocks usually are priced over a penny, occupying a price range at or close to $1, though some are priced a fraction of a penny. Often referred to as micro-cap equities, the Securities & Exchange Commission classifies these types of securities as being $5 or less. Over-the-counter stocks are NOT listed on any of the formal exchanges.

So, penny stocks frequently fit in this segment, though many dodge this category. Over-the-counter (OTC) equities are stated to be risky as they aren’t contingent to the listing and reporting requirements of the reputed commodity exchanges.

Register in the Bar Below to Obtain Breaking Alerts on Shares That Are Set to Make a Move!

Penny shares can be listed on NASDAQ or other known stock exchanges, although many more cannot be found there. A major percentage of penny stocks are listed on the so-named ‘pink sheets’, i.e., daily news of OTC shares. They can even be seen on the ‘Over-the-Counter Bulletin Board.’ Commodities listed on the OTCBB fail to fulfill the listing guidelines of the NYSE or other known exchanges, although they are mandated to file financial statements with known regulators, such as the SEC. Penny shares are inexpensive, thus attractive to shareholders who lack the funds to buy comparatively expensive blue-chip stocks from large firms.

Penny stocks boast immense profit potential. Because these stocks trade cheap, even a slight jump in price turns to be profitable. Look out, however, because frequently shareholders may have trouble getting a decent amount of details about penny stocks. These kinds of shares tend to be latest in news, with almost no track record for investors research.

In addition, penny stocks show lack of market activity, with poor liquidity, making them difficult to sell. Poor liquidity results in penny stocks to be open to price influence.

A shady trader can simply buy large sums of shares, temporarily leading up the price, crafting artificial demand.

Disclaimer: Nothing mentioned in this publication is planned to constitute legal, securities, tax, or investment advice, nor a viewpoint regarding the relevance of any investment, nor any type of solicitation. The general information mentioned in this article should not be acted upon without getting specific tax, legal and investment advice from a certified professional.

More notable recent BELLUS Health Inc (OTCMKTS:BLUSF) news were published by: which released: “Bellus Health Plummets After Protein-Fighting Drug Fails Test” on June 20, 2016, also with their article: “BRIEF-Bellus Health and the NEOMED Institute announce agreement for …” published on February 28, 2017, published: “BELLUS Health Announces Grant of New US Patent Covering Lead Compound for …” on April 24, 2017. More interesting news about BELLUS Health Inc (OTCMKTS:BLUSF) were released by: and their article: “BELLUS Health: Results From KIACTA Phase 3 Clinical Trial Expected In Mid-2016” published on November 18, 2015 as well as‘s news article titled: “Bellus Health Developing Shigamab For The Treatment Of STEC-HUS” with publication date: October 07, 2015.

BELLUS Health Inc. is a drug development firm focused on rare diseases. The company has market cap of $16.45 million. The business activities of the Company are development of the Company’s core technology platform, amyloid inhibitors, which focus on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils, which are the underlying causes of certain diseases. It currently has negative earnings. The Firm operates in the business segment of development of drugs for health solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.